2020 has highlighted the systemic injustice that persists due to institutional inequity in our country. As a patient-centric biopharmaceutical company, we must address the health disparities that result from this continuing inequity. The pandemic has underscored this harsh reality, as people of color, particularly African Americans, endure higher levels of illness and death than White Americans due to the COVID-19 virus.
At Mallinckrodt, Inclusion and Diversity (I&D) is a core strength of our organization and we are routinely recognized nationally as a leader in this discipline. By lifting up diverse voices, we help assure that we […]
Mallinckrodt employee Richard Broadus spent a recent afternoon leading a hands-on lab training for four young adults interested in pursuing STEM careers. The participants, who ranged in age from 22 to 32 years old, were […]
For the third year in a row, Mallinckrodt’s Inclusion and Diversity (I&D) Council was ranked one of the top 10 in the U.S. by PRISM International. PRISM’s annual ERG & Council Honors Award recognizes the […]